Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2021 October Clinical practice Combination regimen effective in patients with R/R classical Hodgin Lymphoma Read more
2021 October Clinical trials Daratumumab maintenance therapy in patients with newly diagnosed MM who received ASCT Read more
2021 October Pharma News Long-term clinical outcomes of tisagenlecleucel in the JULIET trial Read more
2021 October Science CEBPA-bZip mutations are associated with favourable prognosis in de novo AML Read more
2021 September Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: BERT HEYRMAN Read more
2021 September Clinical practice Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed/... Read more
Top
